Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Patent
1996-04-26
1998-12-01
Kight, John
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
4241441, 4241301, 4241791, 424 153, 5303877, 5303881, 5303913, A61K 5110, C07K 1600
Patent
active
058433988
ABSTRACT:
Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.
REFERENCES:
patent: 4331647 (1982-05-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4444744 (1984-04-01), Goldenberg
patent: 4472371 (1984-09-01), Burchiel et al.
patent: 4724213 (1988-02-01), Epstein
patent: 4735210 (1988-04-01), Goldenberg
patent: 4921690 (1990-05-01), Beatty et al.
patent: 5034223 (1991-07-01), Abrams et al.
patent: 5120525 (1992-06-01), Goldenberg
patent: 5273738 (1993-12-01), Matthews et al.
patent: 5595721 (1997-01-01), Kaminski et al.
Buchsbaum et al, "Therapy with Unlabeled and .sup.131 I-Labeled Pan-B-Cell Monoclonal Antibodies in Nude Mice Bearing Raji Burkitt's Lymphoma Xenografts", Cancer Research, 52:6476-6481 (1992) no month provided.
Buchsbaum et al., "Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody", Cancer Research, 52:637-642 (1992) no month provided.
Czuczman et al., "A Phase 1 Dose Escalation Trial of .sup.131 Labeled Monoclonal antibody OKB7 in Patients with B Cell Lymphoma", Fourth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Abstract #55 (Sep. 1992).
DeNardo et al., "Fractionated Radioimmunology of B-Cell Malignancies with .sup.131 I-Lym-1", Cancer Research (Suppl.), 50:1014s-1016s (Feb. 1990).
Eary et al., "Imaging and Treatment of B-Cell Lymphoma" Journal of Nuclear Medicine, 31(8):1257-1268 (Aug. 1990).
Eary et al., "Treatment of B-Cell Lymphoma with I-131 Labelled Murine Monoclonal Antibodies", Proceedings of the 35th Annual Meeting, Scientific Papers, 29(5) Abstract 70 (1988) month not provided.
Ettinger et al., "Phase I-II Study of Isotopic Immunoglobulin Therapy for Primary Liver Cancer" Cancer Treatment Reports, 66(2):289-297 (Feb. 1982).
Goldenberg et al., "Targeting, Dosimetry, and Radioimmunotherapy of B-Cell Lymphomas with Iodine-131-Labeled LL2 Monoclonal Antibody", Journal of Clinical Oncology, 9(4):548-564 (Apr. 1991). I!Anti-B1 (Anti-CD20) Antibody", New England Journal of Medicine, 329:459-465 (Aug. 1993).
Kaminski et al., "Initial Clinical Radioimmunotherapy Results with 131-I-Anti-B1 (Anti CD20) Refractory B-Cell Lymphoma", Fourth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Abstract #57 (Sep. 1992).
Kaminski et al., "131-I Anti-B1: Initial Clinical Evaluation in B-Cell Lymphoma", Third Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Abstract No. 144 (Nov. 1990).
Letvin et al., "Use of Radiolabeled Monoclonal Anti-B1 Antibody for B Lymphocyte Imaging in Rhesus Monkeys", Nucl. Med. Biol., 14(2):99-105 (1987) no month provided.
Macklis et al., "Induction of Programmed Cell Death in Malignant Lymphomas After Radioimmunotherapy", Fourth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Abstract #39 (Sep. 1992).
Macklis et al., "Cell Cycle Alterations, Apoptosis, and Reponse to Low-Dose-Rate Radioimmunotherapy in Lymphoma Cells" Int. J. Radiation Oncology Biol. Phys., 27:643-650 (1993) month not provided.
Macklis et al., "Radiobiologic Basis of Lymphoma Radio-Immunotherapy", Radiation Oncology Biol. Phys., vol. 24, Supplement 1, p. 184, Abstract #101 (1992) month not provided.
Order, "Monoclonal Antibodies: Potential Role in Radiation Therapy and Oncology", Int. J. Radiation Oncology Biol. Phys., 8(7):1193-1201 (1982) month not provided.
Order et al., "Phase I-II Study of Radiolabeled Antibody Integrated in the Treatment of Primary Hepatic Malignancies", Int. J. Radiation Oncology Biol. Phys., 6:703-710 (1980) month not provided.
Parker et al., "Radioimmunotherapy of Human B-Cell Lymphoma with .sup.90 Y-Conjugated Antiidiotype Monoclonal Antibody", Cancer Research, (Suppl.) 50:1022s-1028s (Feb. 1990).
Press et al., "Treatment of Refractory Non-Hodgkin's Lymphoma with Radiolabeled MB-1 (Anti-CD37) Antibody", Journal of Clinical Oncology, 7(8):1027-1038 (Aug. 1989).
Press et al., "Monoclonal Antibody 1F5 (Anti-CD20) Serotherapy of Human B Cell Lymphomas", Blood, 69:584-591 (1987) month not provided.
Press et al., "Radiolabeled Antibody (RAb) Therapy of Relapsed B Cell Lymphomas", Lymphom, Abstract #1077 (Apr. 1992).
Stashenko et al., "Characterization of a Human B Lymphocyte-Specific Antigen", Journal of Immunology, 125(4):1678-1685 (Oct. 1980).
Weinstein et al., "Monoclonal Antibodies in the Lymphatics: Toward the Diagnosis and Therapy of Tumor Metastases", Science, 218:1334-1337 (Dec. 1982).
"Immunomedics Reports on Lymphoma Imaging and Therapy Progress at Cancer Conference", New Jersey, Cancer Research Weekly (1993) month not provided.
Badger, C.C., et al., Experimental Radioimmunotherapy with I-131-Antibody Against a Differentiation Antigen, J. Nuclear Med., 26(5):P67 (1985).
Badger, C.C., et al., Experimental Radioimmuotherapy of Murine Lymphoma with .sup.131 I-Labeled Anti-T-Cell Antibodies, Can. Res., 46:6223-6228 (1986).
Butchko Gregory M.
Glenn Stephan D.
Kaminski Mark S.
Wahl Richard L.
Coulter Pharmaceutical, Inc.
Hartley Michael G.
Kight John
Regents of the University of Michigan
LandOfFree
Radioimmunotherapy of lymphoma using anti-CD20 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radioimmunotherapy of lymphoma using anti-CD20 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radioimmunotherapy of lymphoma using anti-CD20 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2393189